Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

Nexentis (NASDAQ:NXTS) announced that subsidiary MitoCareX Bio completed a broad structural analysis of human SLC transport proteins.

Rhea-AI Summary

Nexentis (NASDAQ:NXTS) announced that subsidiary MitoCareX Bio completed a broad structural analysis of human SLC transport proteins. The work extends its MITOLINE® algorithm beyond mitochondrial SLC25 carriers, identifying additional SLC proteins that appear compatible with MITOLINE-enabled 3D modeling for hard-to-treat cancers and inflammatory metabolic diseases.

Positive

• Completion of broad structural analysis of human SLC transport proteins
• Identification of additional non-SLC25 targets compatible with MITOLINE® ruleset
• Potential expansion of small-molecule discovery into more disease-relevant transporters
• Reuse of existing MITOLINE® discovery engine across mitochondrial and non-mitochondrial SLC targets

Negative

• None.

Argus Jun 17 session

-8.25% close to close Open Argus

Details

News Market Reaction – NXTS

On Jun 17, the day this news came out, NXTS closed 8.25% below the previous close.

Data tracked by StockTitan Argus for the Jun 17 session.

Key Figures

Price move: 5.05% Current price: $5.82 Trading volume: 6,302,220 shares +5 more

Price move

5.05%

Change in last 24 hours pre-news

Current price

$5.82

Latest price vs 200-day MA $5.06

Trading volume

6,302,220 shares

Today vs 20-day average 343,155 shares

Shares offered

311,876 shares

Registered direct offering per 424B5 dated 2026-06-15

Offering price

$4.008 per share

Price for common stock in 424B5 prospectus supplement

Warrants issued

311,876 warrants

Concurrent private placement to same investors

Gross proceeds

$1,249,999.08

Estimated before expenses from 424B5 offering

Short interest

5.73% of float

Days to cover 1.71 on float 401,250 shares

Historical Context

4 past events · Latest: May 18

4 events

1. May 18

   R&D milestone

   24h Move

   +10.8%

   Subsidiary reported optimized hit molecule with improved pharmaceutical properties.

2. May 13

   R&D milestone

   24h Move

   +1.7%

   Announced first drug discovery milestone at MitoCareX using MITOLINE® modeling.

3. May 05

   IP/trademark update

   24h Move

   +1.5%

   U.S. trademark registration approval for MITOLINE™ algorithm platform.

4. Mar 13

   Corporate branding

   24h Move

   +0.0%

   Launch of new corporate website highlighting AI-driven biotech platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

slc transport proteins, solute carrier, mitoline®, sequence analysis and alignment algorithm, +4 more

8 terms

slc transport proteins medical

"completed a broad structural analysis of human SLC (Solute Carrier) transport proteins"

SLC transport proteins are a large family of membrane proteins that move small molecules — such as nutrients, ions, metabolites and many drugs — into and out of cells, acting like gates or shuttle buses across cell membranes. They matter to investors because they are common drug targets and can determine how well medicines are absorbed, distributed or cleared, serve as disease biomarkers, and therefore influence a drug’s effectiveness, safety profile and commercial potential.

solute carrier medical

"broad structural analysis of human SLC (Solute Carrier) transport proteins"

Solute carrier proteins are membrane gateways that move nutrients, ions and small molecules into and out of cells; they are a large family of transport proteins that control what enters cells and how drugs are absorbed and distributed. Investors care because these carriers influence drug effectiveness, side effects and disease mechanisms, making them common targets for therapies and diagnostics—think of them as cellular doors that can determine whether a medicine reaches its target.

mitoline® technical

"This work builds on MITOLINE®, MitoCareX’s proprietary sequence analysis and alignment algorithm"

Mitoline® is a trademarked name for a specific therapeutic compound or drug candidate being developed by a biopharmaceutical company. For investors it represents an asset in a company’s research pipeline—similar to a prototype product—whose progress through testing, approvals and commercialization can materially affect future revenue and risk. Tracking updates about Mitoline® helps investors assess potential market size, regulatory milestones and the likelihood of clinical or commercial success.

sequence analysis and alignment algorithm technical

"MITOLINE®, MitoCareX’s proprietary sequence analysis and alignment algorithm, which to date has been used"

A sequence analysis and alignment algorithm is a computer method that compares biological sequences—like DNA, RNA or proteins—to find matching sections, differences and likely evolutionary relationships. Think of it as lining up sentences to spot shared words or rewrites; that comparison helps researchers identify targets, predict function and detect mutations. Investors care because these algorithms underpin drug discovery, diagnostics and biotech claims, influencing how quickly a candidate advances, the strength of intellectual property, and the likelihood of regulatory success.

3d modeling technical

"used to prepare mitochondrial SLC25 carrier proteins for reliable 3D modeling in support of structure-based drug discovery"

A digital process for creating and manipulating three-dimensional representations of products, buildings, body parts, or scenes that can be viewed, rotated and tested on a computer. Think of it as a virtual clay model or blueprint that lets designers and engineers try ideas, find flaws, and simulate performance before spending money on physical prototypes. For investors, 3D modeling can speed time-to-market, cut development costs, enable custom production, and open recurring software or service revenue streams, all of which affect a company’s competitiveness and margins.

virtual screening workflows technical

"explore the use of MITOLINE®-derived 3D models as part of its virtual screening workflows"

Virtual screening workflows are computerized processes that sift through large libraries of chemical compounds to identify those most likely to interact with a biological target, acting like a smart search engine that narrows millions of options to a manageable shortlist. For investors, these workflows matter because they can speed drug discovery, cut early-stage costs and reduce scientific risk, making research programs more efficient and potentially increasing the value of R&D pipelines.

amino acid sequences medical

"identified additional SLC proteins outside the SLC25 family, whose amino acid sequences appear compatible"

Amino acid sequences are the specific order of small chemical building blocks that link together to form a protein, like letters forming words that determine a recipe’s final dish. Investors care because that order controls how a therapeutic, vaccine, or diagnostic behaves, which affects patent protection, manufacturing complexity, regulatory approval, safety and effectiveness, and therefore a product’s commercial value and risk.

small-molecule discovery medical

"ongoing efforts to expand and refine its small-molecule discovery capabilities"

Small-molecule discovery is the process of finding and refining low-weight chemical compounds that can interact with specific biological targets to treat disease. Think of it as designing a tiny key to fit a biological lock; successful candidates can be patented, tested in trials, and turned into medicines. Investors care because breakthroughs can create high-value drug candidates, reduce development risk, and potentially generate long-term revenue if they reach the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), today reported that it has completed a broad structural analysis of human SLC (Solute Carrier) transport proteins as part of its ongoing efforts to expand and refine its small-molecule discovery capabilities.

This work builds on MITOLINE^®, MitoCareX’s proprietary sequence analysis and alignment algorithm, which to date has been used to prepare mitochondrial SLC25 carrier proteins for reliable 3D modeling in support of structure-based drug discovery in hard-to-treat cancers and inflammatory metabolic diseases.

Based on this new analysis, MitoCareX has identified additional SLC proteins outside the SLC25 family, whose amino acid sequences appear compatible with the MITOLINE^® ruleset, suggesting that these transporters may also be amenable to MITOLINE-enabled structural modeling. As a next step, the company intends to explore the use of MITOLINE^®-derived 3D models as part of its virtual screening workflows for the selected non-mitochondrial SLC targets, with the goal of potentially expanding its small-molecule discovery efforts into additional disease-relevant transport proteins.

By building on the same discovery engine already used for its mitochondrial SLC25 program, MitoCareX aims to increase the range of clinically important transporters it can address while maintaining a focused, computationally driven approach to generating novel small-molecule candidates.

"We are encouraged by MitoCareX’s continued momentum, following the recent announcement of the optimized hit molecule and now with the successful completion of this broad structural analysis of additional SLC transport proteins," said David Palach, CEO of Nexentis. "These achievements highlight the strength and versatility of our MITOLINE^® platform and MitoCareX’s ability to identify additional transporters that can potentially benefit from MITOLINE-enabled 3D modeling in the future. We believe that MitoCareX possesses the scientific expertise and technological capabilities to deliver meaningful breakthroughs in the treatment of hard-to-treat cancers and inflammatory metabolic diseases."

About Nexentis Technologies Inc.

Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd, a drug discovery company engaged in targeting cancer and inflammatory metabolic disease indications through the mitochondrial SLC25 protein family. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

For additional details, please visit www.nexentistech.com

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses MitoCareX’s intention to explore the use of MITOLINE®-derived 3D models as part of its virtual screening workflows for the selected non-mitochondrial SLC targets, with the goal of potentially expanding its small-molecule discovery efforts into additional disease-relevant transport proteins, how MitoCareX aims to increase the range of clinically important transporters it can address while maintaining a focused, computationally driven approach to generating novel small-molecule candidates and its belief that MitoCareX possesses the scientific expertise and technological capabilities to deliver meaningful breakthroughs in the treatment of hard-to-treat cancers and inflammatory metabolic diseases. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nexentis (NASDAQ:NXTS) announce about MitoCareX Bio on June 17, 2026?

Nexentis reported that MitoCareX Bio completed a broad structural analysis of human SLC transport proteins. According to Nexentis, this analysis supports expanding its MITOLINE®-based small-molecule discovery for hard-to-treat cancers and inflammatory metabolic diseases using structure-based 3D modeling.

How does the MITOLINE® platform support Nexentis (NXTS) cancer and metabolic disease programs?

MITOLINE® is a proprietary sequence analysis and alignment algorithm used to prepare SLC25 carrier proteins for reliable 3D modeling. According to Nexentis, extending MITOLINE® to additional SLC transporters may enable structure-based discovery of novel small molecules for hard-to-treat cancers and inflammatory metabolic diseases.

What new SLC targets did MitoCareX identify for Nexentis (NASDAQ:NXTS)?

MitoCareX identified additional human SLC proteins outside the SLC25 family whose amino acid sequences appear compatible with the MITOLINE® ruleset. According to Nexentis, these transporters may also be suitable for MITOLINE-enabled 3D structural modeling and inclusion in its small-molecule discovery workflows.

What are the next steps for MitoCareX Bio in Nexentis’s SLC program?

MitoCareX plans to use MITOLINE®-derived 3D models in virtual screening workflows for selected non-mitochondrial SLC targets. According to Nexentis, the goal is to potentially expand small-molecule discovery into additional disease-relevant transport proteins while keeping a focused, computational approach.

How could the MitoCareX SLC analysis impact Nexentis (NXTS) drug discovery pipeline?

The completed analysis could widen the range of clinically important transporters addressable with MITOLINE®-based modeling. According to Nexentis, leveraging the same discovery engine across more SLC targets may support generation of novel small-molecule candidates for hard-to-treat cancers and inflammatory metabolic diseases.

What did Nexentis management say about MitoCareX Bio’s recent progress?

CEO David Palach highlighted MitoCareX’s momentum, citing an optimized hit molecule and completion of the broad SLC analysis. According to Nexentis, these milestones demonstrate the strength and versatility of the MITOLINE® platform and MitoCareX’s scientific and technological capabilities.